CDK 7 Inhibitors - Market Size, Target Population, Competitive Landscape & Market Forecast - 2036

Key Highlights

• CDK7 inhibitors represent a promising therapeutic class under clinical investigation for multiple malignancies including hepatocellular carcinoma (HCC), leukemia, breast cancer, non-Hodgkin lymphoma (NHL), small cell lung cancer (SCLC), and triple-negative breast cancer (TNBC).
• Preclinical studies have shown that CDK7i causes cell cycle arrest, apoptosis, and repression of transcription, particularly of super-enhancer-associated genes in cancer, and have demonstrated their potential for overcoming resistance to cancer treatments.
• Although no CDK7 inhibitor has been approved by the US FDA to date, the therapeutic landscape is advancing through clinical development, with emerging players such as Carrick Therapeutics (samuraciclib), Qurient Therapeutics (mocaciclib), and Recursion (REC-617) evaluating selective CDK7 inhibitors in clinical trials.
• The competitive landscape remains nascent, with only a few clinical-stage contenders, creating a window for pipeline differentiation through biomarker-led development, optimized dosing strategies, and expansion into early-line settings.

The “CDK 7 Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast - 2036” report delivers an in-depth understanding of CDK 7 Inhibitors, addressable patient pool, competitive landscape, and future market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan.

The CDK 7 Inhibitors market report provides insights around existing treatment practices in patients with CDK 7 Inhibitors, approved (if any) and emerging CDK 7 Inhibitors, market share of individual therapies, patient pool eligible for treatment with CDK 7 Inhibitors, along with current and forecasted 7MM CDK 7 Inhibitors market size from 2022-2036 by therapies and by indication. The report also covers current unmet needs and challenges while incorporating new classes in treatment paradigm, variations in accessibility and acceptability of new CDK 7 Inhibitors in different geographies, along with insights on CDK 7 Inhibitors pricing reimbursements to curate the best opportunities and assess the market’s potential.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain), and the UK
• Japan

Study Period: 2022-2036

CDK 7 Inhibitors Overview

Cyclin-dependent kinase 7 (CDK7) is a member of the CDK family of serine/threonine protein kinases and participates in the regulation of the cell cycle and mRNA transcription.

CDK7 inhibitor development is increasingly shifting toward biomarker-defined, transcriptionally addicted tumors, with patient selection emerging as a key differentiator for maximizing efficacy while mitigating class-associated toxicities.

Target Patient Pool Analysis

• According to the American Cancer Society (2025), HR+ HER2-negative breast cancer accounts for 70% of all breast cancers in the United States.
• According to Breast cancer organization (2023), nearly 30% of women diagnosed with early-stage breast cancer develop metastatic disease.
• According to CDC in 2023, 155,662 cases of colon and rectum cancer were reported. The age-adjusted incidence rate was 41.4 per 100,000 among males and 32.5 per 100,000 among females, indicating a higher incidence among males.
• As per DelveInsight’s analysis, the total incident cases of HR+/HER2- breast cancer in the US comprised 150,000 cases in 2025 and are projected to increase during the forecast period.
• As per DelveInsight analysis, the total incident cases of TNBC in the United States comprised 47,000 cases in 2025.

CDK 7 Inhibitors Drug Chapters

The drug chapter segment of the CDK 7 Inhibitors report encloses a detailed analysis of marketed therapies and late-stage (Phase III and Phase II) therapies. It also helps understand the CDK 7 Inhibitors clinical trial details, pharmacological action, agreements and collaborations related to CDK 7 Inhibitors, their approval timelines, patent details, advantages and disadvantages, latest news and press releases.

CDK 7 Inhibitors Emerging Drugs

Samuraciclib (CT7001): Carrick Therapeutics

Samuraciclib is the most advanced oral CDK7 inhibitor in clinical development. The primary indication for samuraciclib is HR+, HER2- breast cancer. In addition, it has the potential to treat many other cancer types. Samuraciclib has demonstrated a favorable safety profile and encouraging efficacy in early clinical studies. It has been granted Fast Track designation (FTD) from the US Food and Drug Administration (FDA) for use in combination with fulvestrant for the treatment of CDK4/6i resistant HR+, HER2- advanced breast cancer. Carrick is further validating these two selection strategies in two additional Phase II studies reading out later this year with the intent to advance to Phase III in 2026.

Mocaciclib (Q901): Qurient Therapeutics

Q901 is a highly selective CDK7 inhibitor that disrupts tumor cell division cycle progression and blocks DNA damage repair, resulting in tumor cell apoptosis. Q901 demonstrated strong tumor growth inhibition in multiple cancer models including HR+ breast cancer, prostate cancer, ovarian cancer, and small cell lung cancer as a single agent, as well as in combination with other therapies. Q901 in combination with fulvestrant is in a clinical trial for HR+ breast cancer patients who are refractory to CDK4/6 inhibitor and estrogen therapy combination. It is in the Phase I/II of development.

REC-617 (GTAEXS617): Exscientia (Recursion)

REC-617 is a reversible, non-covalent small molecule CDK7 inhibitor being developed for the treatment of multiple advanced solid tumor indications. ELUCIDATE is an ongoing Phase I/II study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose of REC-617 in patients with advanced solid tumors.

Recent Developments in the CDK7 Inhibitors Market

• In August 2026, Recursion announced in there company presentation that early Phase I safety and PK data for REC-617 in combination therapy is anticipated in 1H 2027.
• In June 2026, Qurient announced that first patient has been dosed in a Phase II clinical study evaluating mocaciclib (Q901) in combination with fulvestrant for treatment of HR+ breast cancer.
• In December 2025, Carrick Therapeutics announced positive Phase II SUMIT-BC results evaluating samuraciclib, an oral first-in-class CDK7 inhibitor, in combination with fulvestrant in patients with second-line advanced HR+/HER2- breast cancer previously treated with a CDK4/6 inhibitor. The results were presented as a late-breaking poster at the 2025 SABCS.

Drug Class Insights

The Drug Class Insights section will provide comprehensive information on CDK 7 Inhibitors as a class. This will include a broad overview of the class and its role in treating specific conditions. Insights may cover the historical clinical development of CDK 7 Inhibitors, their mechanism of action, their subtypes and future commercial prospects. Additionally, the section will provide detailed information about current trends, challenges, and future prospects for this class of drugs.

CDK 7 Inhibitors Market Outlook

This section will include details on changing CDK 7 Inhibitors market dynamics post initiation of clinical development activities of the inhibitor. It will also provide a detailed summary and comparison of all the therapies being developed by leading players in this space. This section will highlight the advantages of one therapy over the other after assessment based on parameters such as data availability in the form of safety and efficacy, number of patients enrolled in each trial, and trial’s inclusion criteria. There will be a Key focus on the importance of development and need for the commercial success of these targeted therapies to achieve treatment goals that physicians and patients are looking for. It will also sum up all the early stage players active in this space.

CDK 7 Inhibitors Drugs Uptake

This section focuses on the uptake rate of potential CDK 7 Inhibitors already launched and expected to be launched in the market during 2022-2036, which depends on the competitive landscape, safety, efficacy data, and order of entry. It is important to understand that the key players evaluating their novel therapies in the pivotal and confirmatory trials should remain vigilant when selecting appropriate comparators to stand the greatest chance of a positive opinion from regulatory bodies, leading to approval, smooth launch, and rapid uptake.

CDK 7 Inhibitors Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III and Phase II stages. It also analyzes key players involved in developing targeted therapeutics.

CDK 7 Inhibitors Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for CDK 7 Inhibitors.

KOL Views

To keep up with current and future market trends, we incorporate Key physicians, Therapy Area Researcher’s, and other Industry Experts’ opinions working in the domain through primary research to fill in the data gaps and validate our secondary research. 25+ Key Opinion Leaders (KOLs) were contacted for insights on CDK 7 Inhibitors’ incorporation in the evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, drug uptake, along with challenges related to accessibility.

Qualitative Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and Analyst views. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the analyst’s discretion and assessment of the cost analysis and existing and evolving treatment landscape.

Market Access and Reimbursement

This section will include insights around the standard HTA pricing, recent reformations in 2024 and modifications in reimbursement process in the 7MM. For example, In the United States, a multi payer model exists when it comes to drug pricing regime, which is currently undergoing significant changes, with recent federal legislation, such as the Prescription Drug Pricing Reform provisions of the Inflation Reduction Act, significantly altering the pricing regime under certain federal programs. Whereas in Germany, the market access differs from the systems followed in many other countries as no pricing and reimbursement approval is required during launch of a new therapy.

Moreover, this section will also provide details on reimbursement of approved therapy, if any.

Scope of the Report

• The report covers a segment of key events, an executive summary, target patient pool, epidemiology and market forecasts, information around patient journey and varying biomarker testing rates
• Additionally, an all-inclusive account of the current and emerging therapies drug chapters, insights on CDK 7 Inhibitors addressable patient pool
• A detailed review of the CDK 7 Inhibitors market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, and treatment preferences that help in shaping and driving the 7MM CDK 7 Inhibitors market.
• Market Size of Inhibitors by therapies and indication will be provided

CDK 7 Inhibitors Report Key Strengths

• 11 Years CDK 7 Inhibitors Market Forecast
• The 7MM Coverage
• CDK 7 Inhibitors Competitive Landscape of current and emerging therapies
• CDK 7 Inhibitors Total Addressable patient population
• Drugs Uptake and Key Market Forecast Assumptions
• Approved and Emerging therapy Profiles
• Physician’s perspectives/KOL opinions
• Biomarker testing and Patient journey
• Qualitative Analysis (SWOT and Analyst Views)
• CDK 7 Inhibitors Market Size by therapy and indication
• Existing and Future Market Opportunity
• Unmet Needs

FAQs

• What was the CDK 7 Inhibitors total market size, the market size by therapies, market share (%) distribution in 2022, and what would it look like by 2036? What are the contributing factors for CDK 7 Inhibitors market growth?
• Which KRAS Inhibitor is going to be the largest contributor by 2036?
• What is the market access and reimbursement scenario of CDK 7 Inhibitors?
• What are the pricing variations among different geographies?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies?
• Patient acceptability in terms of preferred treatment options as per real-world scenarios?

Reasons to Buy

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the CDK 7 Inhibitors Market.
• Understand the existing CDK 7 Inhibitors market opportunities and future trends in varying geographies
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Highlights of access and reimbursement policies of approved therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
• To understand Key Opinion Leaders’ perspectives around the accessibility and acceptability of emerging treatment options along with unmet need of current therapies
• Details on report methodology, top indications covered, market assumptions, patient journey and KOLs to strengthen the pharmaceutical companies’ development and launch strategy.

This product will be updated with the latest data at the time of order. Consequently, dispatch time for this product will be 7-10 business days.